Centre for NanoHealth Future Healthcare - PowerPoint PPT Presentation

1 / 36
About This Presentation
Title:

Centre for NanoHealth Future Healthcare

Description:

Title: PowerPoint Presentation Author: I W Last modified by: Steve Conlan Created Date: 9/21/2004 5:40:17 PM Document presentation format: On-screen Show (4:3) – PowerPoint PPT presentation

Number of Views:129
Avg rating:3.0/5.0
Slides: 37
Provided by: IW
Category:

less

Transcript and Presenter's Notes

Title: Centre for NanoHealth Future Healthcare


1
Centre for NanoHealthFuture Healthcare
  • Dr Steve Conlan
  • Director - Centre for NanoHealth
  • Institute of Life Science
  • School of Medicine

2
Overview
  • Nanotechnology
  • NanoHealth
  • Impact of NanoHealth
  • Centre for NanoHealth
  • Challenges and Opportunities
  • RD

3
Please turn off your Nanotechnology based
devices.
4
The nano-scale
5
What is NanoHealth?
6
Nanotechnology
  • Ability to manipulate and control the properties
    and interaction of material where at least 1-D is
    nm.
  • Structural
  • Mechanical
  • Electronic
  • Optical
  • Chemical
  • Biological
  • Computational
  • Modelling

Multidisciplinary
For Healthcare
7
The impact of NanoHealth
8
NanoHealth
has the potential to impact on the prevention,
early and reliable diagnosis and treatment of
diseases.
European Technology Platform on NanoMedicine
Vision Paper (2005)
  • NanoHealth embraces five main sub-disciplines
  • that in many ways are overlapping
  • Analytical Tools
  • Imaging Tools
  • Materials and Devices
  • Novel Therapeutics and Drug Delivery Systems
    Nanomedicines
  • Clinical, Regulatory and Toxicological Issues

ESF forward look on Nanomedicine (2005)
9
Impact on Healthcare
  • Diagnosing and treating diseases
  • Enhancing early intervention
  • Non-hospital environments
  • Personalised Medicine

10
Economic Impact
11
Economic Impact
12
Global Networks/Global Investment EU, US, South
America and Asia
Alliance for Nanohealth
ETP for Nanomedicine
13
Centre for NanoHealth
14
Partnership for Success
  • Institute of Life Science
  • 52m collaborative venture between IBM, Swansea
    University, WAG, opening its doors in 2007
  • Home in the Medical School, 25 specialist teams
    (27 Professors and 220 Research active staff)

Multidisciplinary Nanotechnology Centre More
than 5M funding in 2002 from HEFCW, Royal
Society/ Wolfson Foundation, SRIF and Swansea
University Home in Engineering, major research
centre (20 academic staff, 20 RAs and 40 PhD
students)
Outstanding RAE 2008 results (THES) MNC 5th out
of 52 in UK in General Engineering, 80 of
activity rated 4 and 3 ILS 7th out of 70 in UK
in Allied and Professional Health, 55 of
activity 4 and 3
15
Partnership for Success
  • Successfully managed HEFCW project
  • Model interdisciplinary centre
  • Self-sustaining (2M per year)
  • Strong links with business/IP
  • Pan-Wales focus for nanotech
  • Successfully managed Objective 1 project
  • On time - On budget
  • Outputs met sustainability/job creation/strong
    links with business/IP
  • Blue C IBM partnership
  • Interdisciplinary research base
  • University NHS Trust
  • Patient base of 600,000
  • Partnership with ILS and MNC
  • Joint MNC and ILS laboratories in Morriston
    Hospital
  • Commitment to CNH

16
Centre for NanoHealth
  • 22M EU Convergence funded project, started
    January 2009
  • 12 new staff (8 academic, 4 project management
    and delivery).
  • 13M investment in state of the art open access
    nano- and bio-facilities.
  • Industry to come and work with us, access to
    facilities, expertise and incubation space.

17
Centre for NanoHealth
18
Project Funding
  • 22 Million, 5 year Knowledge Economy project
  • Supported by
  • WEFO 10.5 Million
  • DHSS 1.5 Million
  • Swansea University 7.6 Million
  • Industry 2.5 Million

19
CNH Targets Deliverables
  • Establishing a European RD Centre of Excellence
  • Assisting 400 Enterprises (gt80 Welsh SMEs)
  • Assisting 100 Individuals
  • Creating 450 Jobs
  • Achieving sustainability by 2014
  • Through Welsh, UK, Industrial and EU funding

20
CNH
Building opens Q3 2011 Facilities available now
  • Bio-suite
  • NanoToxicology
  • Cell Imaging
  • Tissue Engineering
  • Molecular biology
  • Microbiology
  • Nano-suite
  • Class 100/1000 dirty clean room
  • Bio-clean room
  • Nanostructure growth
  • SEM AFM/SNOM
  • NMR Rheology
  • Printing and Coating

Direct access to Clinical Trials Unit Patient
imaging (MRICT)
21
Projects challenges opportunities
22
Challenges Opportunities
  • Company recruitment
  • Business development
  • IP
  • State Aid
  • Managing stakeholder expectations
  • Sustainability

23
Company recruitment Business development
  • Project must offer real opportunities to
    businesses across Wales
  • Take the project to the companies
  • Launch Events/BioWales/KTNs etc
  • Initial assistance is only the first step in the
    relationship
  • Ensure multiple entries for engagement
  • Pool of relevant expertise is essential
  • Awareness of funding opportunities is essential
  • Beware of ERDF overload internal/institutional
    management vital

24
CNH
  • Access Clinical/Biomedical/Engineering teams
  • Fully integrated work flow
  • Access at any stage
  • Translational applications
  • Great opportunities in a new area of healthcare

25
IP / IPR
  • IP policy of University has to be flexible
  • Case by case consideration one model DOES NOT
    fit all
  • Primary consideration to companies SHOW
    STOPPER
  • Has to be managed differently to IP generated in
    house
  • Early negotiation
  • Companies understand and appreciate position of
    University
  • State Aid compliance

26
State Aid
  • Necessarily a major consideration under European
    law
  • Documentation from WEFO offers clarity in their
    expectations
  • Seek legal advice on wording used in business
    plans
  • De minimus scheme easy to implement

27
Sustainability RD pipeline
  • Start early
  • Awareness of all opportunities
  • Development pipeline

28
Delivery Team work!!
  • Medicine
  • Engineering
  • Finance
  • Research and Innovation
  • Procurement
  • VCs office
  • ABMUHB
  • External project managers / build team
  • WEFO

Early/Continued/Agreed/Managed engagement
29
CNH operational structure
30
NanoHealth RD
31
(No Transcript)
32
Diagnostics Biosensors
Novel Materials
Electrode
Antigen
Antibody
Nanowire
Ultra-sensitive biosensor for the detection of
bio-markers using bio-compatible ZnO nanowires.
ZnO nanowires (AFM)
33
Cellular Analysis for Clinical Diagnostics
  • Surface topography.
  • Material properties.
  • Spatial resolution 5 - 20 nm.

34
Biosensors / Biomarker Detection
  • Volume additive printing for the integration of
    biosensors with flexible polymer electronics,
    photonics and displays.

35
Centre for NanoHealth
36
Centre for NanoHealth
Write a Comment
User Comments (0)
About PowerShow.com